| 产品描述: | GSK-F1 (Compound F1) is an orally active PI4KA inhibitor with pIC50 values of 8.0, 5.9, 5.8, 5.9, 5.9 and 6.4 against PI4KA, PI4KB, PI3KA, PI3KB, PI3KG and PI3KD, respectively. GSK-F1 can be used for HCV infection research |
| 靶点: |
PI4KA:8.0 (pIC50);PI4KB:5.9 (pIC50);PI3KA:5.8 (pIC50);PI3KB:5.9 (pIC50);PI3KG:5.9 (pIC50);PI3KD:6.4 (pIC50);PI4K |
| 体内研究: |
GSK-F1 (3-40 mg/kg/天;口服;每日两次;最多 14 天) 导致部分小鼠死亡,并导致存活小鼠出现胃肠道异常等不良反应。 |
| 参考文献: |
1. Bojjireddy N, et al. Pharmacological and genetic targeting of the PI4KA enzyme reveals its important role in maintaining plasma membrane phosphatidylinositol 4-phosphate and phosphatidylinositol 4,5-bisphosphate levels. J Biol Chem. 2014 Feb 28;289(9):612 |
| 溶解性: |
Soluble in DMSO |
| 保存条件: |
-80℃(运输条件:冰袋低温运输) |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
1.657 ml |
8.285 ml |
16.569 ml |
| 5 mM |
0.331 ml |
1.657 ml |
3.314 ml |
| 10 mM |
0.166 ml |
0.828 ml |
1.657 ml |
| 50 mM |
0.033 ml |
0.166 ml |
0.331 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |